Study of ACE2 protein levels in COVID-19 patients to predict severity.
Low levels of ‘Angiotensin converting enzyme 2 (ACE2)’ protein are associated with a higher severity and lethality of COVID19 infection.
ACE2 levels will be measured for several groups of COVID19 patients with different clinical developments and, if the ACE2 value allows discrimination between the different groups, they will be evaluated.
If the hypothesis is confirmed, ACE2 levels would provide a prognostic factor of clinical evolution that would be very useful to guide decisions in the hospital context and to define groups at risk of serious infection.
Principal Investigators: Ugo Bastolla Bufalini (CBM), Manuel Fresno Escudero (Co-IP)